Filing Flows › Macrogenics (MGNX) › Q2 2026
Macrogenics (MGNX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Macrogenics (MGNX) reported revenue of $32.8M for the second quarter 2026 (Q2 2026), +378% from a year earlier and +58% from the quarter before. Operating margin was -42.2%, net earnings $19.5M (59.4% of revenue).
Macrogenics, Q2 2026: revenue $32.8M (+378% year over year), operating margin -42.2%, net earnings $19.5M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.8M | +58% | +378% |
| Operating profit | −$13.9M | — | — |
| Net earnings | $19.5M | — | — |
| Operating cash flow | −$40.7M | — | — |
What changed
Revenue was $32.8M in Q2 2026, up 378% year over year and up 58% from the previous quarter. Collaborative and other agreements was the largest line at 78% of revenue. Collaborative and other agreements added $19.9M year over year (up 359%), 77% of the total change.
Operating costs exceeded revenue by $13.9M, an operating margin of -42.2%. Total costs fell 7% while revenue rose 378%. Net earnings were $19.5M. The effective tax rate was 0.0%. Non-operating items added $33.4M, 171% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$40.7M. Non-cash charges added back $708K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $62.9M. Capital expenditures of $806K exceeded it, leaving free cash flow of −$41.6M.
Questions
What was Macrogenics' revenue in the second quarter 2026?
Macrogenics (MGNX) reported revenue of $32.8M for the second quarter 2026 (Q2 2026), +378% from a year earlier and +58% from the quarter before.
Was Macrogenics profitable in the second quarter 2026?
Operating loss was $13.9M (-42.2% of revenue) and net earnings $19.5M.
Source: Macrogenics 10-Q on SEC EDGAR.